Lillian W. Chiang

Dr. Lillian W. Chiang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KRKathryn L. Roche
Kathryn L. Roche
SRStacy Remiszewski
Stacy Remiszewski
MTMatthew J. Todd
Matthew J. Todd
JKJohn L Kulp
John L Kulp
LTLiudi Tang
Liudi Tang
LCLillian W. Chiang
Lillian W. Chiang
Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or virus family, and the pathogen can readily evolve resistance. Host-targeted antivirals can overcome these limitations. The broad-spectrum activity achieved by host targeting can be especially useful in combating emerging viruses and for treatment of diseases caused by multiple viral pathogens, such as opportunistic agents in immunosuppressed patients. We have developed a family of compounds that modulate sirtuin 2, an NAD+-dependent deacylase, and now report the properties of a member of that family, FLS-359. Biochemical and x-ray structural studies show that the drug binds to sirtuin 2 and allosterically inhibits its deacetylase activity. FLS-359 inhibits the growth of RNA and DNA viruses, including members of the coronavirus, orthomyxovirus, flavivirus, hepadnavirus, and herpesvirus families. FLS-359 acts at multiple levels to antagonize cytomegalovirus replication in fibroblasts, causing modest reductions in viral RNAs and DNA, together with a much greater reduction in infectious progeny, and it exhibits antiviral activity in humanized mouse models of infection. Our results highlight the potential of sirtuin 2 inhibitors as broad-spectrum antivirals and set the stage for further understanding of how host epigenetic mechanisms impact the growth and spread of viral pathogens.

18 April 2024 in Antiviral Research
Verified
Journal Article
Closed access
LTLiudi Tang
Liudi Tang
SRStacy Remiszewski
Stacy Remiszewski
ASAndrew Snedeker
Andrew Snedeker
LCLillian W. Chiang
Lillian W. Chiang
TSThomas Shenk
Thomas Shenk

9 August 2023 in Antiviral Research
Verified
Journal Article
Closed access
JCJennifer Cheung
Jennifer Cheung
SRStacy Remiszewski
Stacy Remiszewski
LCLillian W. Chiang
Lillian W. Chiang
Ejaz AhmadEjaz Ahmad
Ejaz Ahmad
MPMohan Pal
Mohan Pal
GCGary Chan
Gary Chan

29 September 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TSThomas E. Shenk
Thomas E. Shenk
JKJohn L Kulp
John L Kulp
LCLillian W. Chiang
Lillian W. Chiang
Direct-acting anti-infective drugs target pathogen-coded gene products and are a highly successful therapeutic paradigm. However, they generally target a single pathogen or family of pathogens, and the targeted organisms can readily evolve resistance. Host-targeted agents can overcome these limitations. One family of host-targeted, anti-infective agents modulate human sirtuin 2 (SIRT2) enzyme activity. SIRT2 is one of seven human sirtuins, a family of NAD+-dependent protein deacylases. It is the only sirtuin that is found predominantly in the cytoplasm. Multiple, structurally distinct SIRT2-targeted, small molecules have been shown to inhibit the replication of both RNA and DNA viruses, as well as intracellular bacterial pathogens, in cell culture and in animal models of disease. Biochemical and X-ray structural studies indicate that most, and probably all, of these compounds act as allosteric modulators. These compounds appear to impact the replication cycles of intracellular pathogens at multiple levels to antagonize their replication and spread. Here, we review SIRT2 modulators reported to exhibit anti-infective activity, exploring their pharmacological action as anti-infectives and identifying questions in need of additional study as this family of anti-infective agents advances to the clinic.